Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Measuring disease activity and severity in scleroderma

P J Clements

    Current Opinion in Rheumatology
    |November 1, 1995
    PubMed
    Summary
    This summary is machine-generated.

    This editorial reviews systemic sclerosis (SSc) natural history and pathophysiology, proposing candidate variables to measure disease activity and severity in clinical trials. Focusing on accurate measurement is crucial for developing effective SSc treatments.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.

    Arthritis and rheumatism·2012
    Same author

    Differences in presentation of younger and older systemic sclerosis patients in clinical trials.

    Clinical and experimental rheumatology·2010
    Same author

    A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients.

    Clinical and experimental rheumatology·2010
    Same author

    Stimulation with type I collagen induces changes in gene expression in peripheral blood mononuclear cells from patients with diffuse cutaneous systemic sclerosis (scleroderma).

    Clinical and experimental immunology·2010
    Same author

    Systemic sclerosis and bilateral lung transplantation: a single centre experience.

    The European respiratory journal·2010
    Same author

    A world of progress in systemic sclerosis.

    Clinical and experimental rheumatology·2009
    Same journal

    New approaches to the management of cutaneous lupus.

    Current opinion in rheumatology·2026
    Same journal

    "Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

    Current opinion in rheumatology·2026
    Same journal

    Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

    Current opinion in rheumatology·2026
    Same journal

    Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

    Current opinion in rheumatology·2026
    Same journal

    Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

    Current opinion in rheumatology·2026
    Same journal

    Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

    Current opinion in rheumatology·2026
    See all related articles

    Area of Science:

    • Rheumatology
    • Clinical Trial Design
    • Disease Measurement

    Background:

    • Published guidelines exist for systemic sclerosis (SSc) disease-modifying treatment trials.
    • Guidelines for evaluating SSc organ-specific treatments are in preparation.
    • The focus is shifting towards robust methods for measuring SSc disease activity and severity.

    Discussion:

    • Several proposals for measuring SSc disease severity have been put forward and are discussed.
    • The review covers current knowledge of SSc natural history.
    • Pathophysiological aspects of SSc are examined in relation to disease measurement.

    Key Insights:

    • Candidate variables that may reflect SSc disease activity are proposed.
    • These variables require evaluation in longitudinal studies.

    Related Experiment Videos

  • Drug trials are a key setting for validating these proposed measures.

    • Outlook:

    • Standardized and validated measures are essential for advancing SSc treatment research.
    • Future research should focus on incorporating these candidate variables into clinical practice.
    • Improved disease activity assessment will facilitate the development of targeted therapies for systemic sclerosis.